Over longer periods of three, five and 10 years, small-cap funds have rewarded their investors handsomely.
Overall slowdown in the economy and growing volumes of unbranded generic medicines in the domestic market are behind poor sales.
'India seems to be on a relatively better wicket compared to other emerging markets.'
The Centre has shared a set of parameters with all states and UTs to enable service providers and monitoring teams under the national COVID-19 vaccination programme to identify any fake COVID-19 vaccines so that they are not administered in the country.
When computing moved to the cloud, it brought a lot of advantages of managing data at scale. Computation of large sets of information sourced from several locations allowed experts to interpret data at scale with flexibility. Artificial intelligence (AI) played a critical role in helping understand patterns which could lead to business insights. In the new scenario, using AI in the cloud is not enough anymore.
In November, DRL registered growth of 28 per cent year-on-year (YoY), which was the highest among peers and double that of the industry growth (14.5 per cent).
These self-appointed well-wishers of AMU are basically for the control or police model of university governance. They have no faith whatsoever in the democratic functioning of the universities, observes Faizan Mustafa, former dean, Faculty of Law, and Registrar, Aligarh Muslim University.
Companies such as Cadila Healthcare, Lupin, and Natco, which sell generic versions of flu medication in the US market, are likely to benefit.
The Appellate Authority for Advance Rulings (AAAR) of Gujarat has held that papad fryums would not attract any goods and services tax (GST) as they are similar to traditional round papads in all respects. In this connection, the appellate authority modified the ruling of the authority for advance rulings (AAR), which had ruled that Fryums would attract 18 per cent GST. The AAAR held that Fryums is a brand and not a generic name of the product, Harpreet Singh, partner, indirect taxes at KPMG in India said while explaining the order.
Fund managers said investors remained positive on the pharma manufacturing activity in India, which further strengthened during the Covid-19 period, on account of restrictions imposed on pharma imports from China.
'I believe it's not the success of RRR or KGF that we must actually investigate but what makes these two films our marquee events,' argues Sreehari Nair.
While Covid-related sales may come down going ahead, analysts expect the company's domestic sales to outperform the market, led by the chronics portfolio, which accounts for 55 per cent of sales.
'The tie-up with Serum Institute Life Sciences brings to the table their strengths in manufacturing and also their vaccine portfolio.'
A screenplay and superstar in perfect tandem, it doesn't get better than this, applauds Sukanya Verma.
Gland Pharma, promoted by China's Fosun, has extended its gains, is up 40 per cent since its listing.
The ICMR Advisory on Purposive Testing Strategy for COVID-19 also said individuals undertaking inter-state domestic travels do not need to get tested either.
Amid multi-tier security, Prime Minister Narendra Modi on Sunday will dedicate India's first 'carbon neutral panchayat' to the nation apart from inaugurating and laying foundation stone of development projects worth over Rs 20,000 crore to give fillip to speedy development of Jammu and Kashmir.
Seeking to develop and rejuvenate 75 water bodies in every district of the country, the prime minister will launch a new initiative named 'Amrit Sarovar', it said.
Feeling forced or creeped out is not only a red flag, but a strong sign of possible deception. Trust your gut!
The intention of the government is to cap prices of drugs that are essential and which the public widely uses.
After a recent fall in profit, Masayoshi Son of SoftBank announced that the Japanese tech investor will look at dramatic cost-cutting. Before he does that, investments in India for calendar year 2022 (CY22) will fall radically, observed sources in the know. Last year, the company had invested around $3.2-3.5 billion in the Indian start-up ecosystem - almost 10 per cent of the total investment the sector received. For CY22, the investments may not even touch $1 billion.
As on July 31, the valuation of his shareholding in the company stood at Rs 9,830 crore.
'We are anticipating that the hiring trend will continue to see double-digit growth at least for the current financial year.'
In Budget 2020-21, the Department of Space has been allocated Rs 13,949.09 crore, of which Rs 8,228.63 crore has been earmarked for capital expenditure.
Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga
'The coronavirus epidemic highlights the need to start thinking more actively about multilateral coordination, including, but not confined to, health emergencies and climate uncertainties,' says Rathin Roy.
'It seems the action against Nupur was because the vice president was in Qatar and officials in his secretariat did not want any embarrassment.'
In a first-of-its-kind scheme, the Indian Railways has installed a squat machine at the Anand Vihar station and 30 squats in front of it will generate a free platform ticket.
Yoga guru Ramdev, who had said he does not need the Covid vaccine as he has protection of yoga and Ayurveda, on Thursday did a somersault, saying he will soon get the jab and described doctors as 'God's envoys on earth'.
Health economist and advisor to the High-Level Expert Group on Universal Health Care, S Selvaraj says that tackling lack of doctors in India will take time to sort out, but providing free drugs can be done immediately.
Sun Pharmaceutical, which is growing its dermatology and ophthalmic specialty business in the US will spend $460 million on R&D.
After a lifetime of showing us what it means to 'act at the top of one's bent and never hit a false note', Mammootty had the good sense, in the third act of his career, to pare down his style, become less mannered, draw directly from life. And getting a performer like that to play characters who seem 'completely dead inside', is, in my view, a betrayal of his legacy, his still-burning ambition, and his still-sharp feelers, observes Sreehari Nair.
Amneal Pharmaceuticals is set to pip Sun Pharma as the fifth largest generics maker in the US, reports Sohini Das.
While companies continue to face regulatory pressure leading to higher costs, they see an uptick from the launch of differentiated and high-margin products
The only category of pharmaceuticals that showed a negative growth in exports this time was herbal products, exports of which stood at $299 million as compared to $ 312 million in the previous year.
The government has also given permission to 20 plants to produce the antiviral drug.
Because it costs a shit-ton of money. Full disclosure: I won't accept a wedding ring that costs Rs 1L or less. But Rs 1L and more seems like a LOT of money. Enough for me to think about better ways to spend it. Stocks? Mutual Funds? SIPs? *GASP* NFTs and Crypto?
'That is how our machinery operates and sees every prisoner.'
With all major US export-oriented drug manufacturing plants in the country up for inspection in 2022, some estimates peg that at least 20-30 per cent of the new product launches lined up for the US will be subject to on-site inspection by the US Food and Drug Administration (USFDA). The last two years saw limited physical inspections due to travel restrictions during the pandemic. "Pre-Covid, the frequency and number of inspections of manufacturing plants in India by USFDA had increased significantly," analysts from ICICI Securities Research noted. "With growing ANDA filings, especially for complex products. "We expect this trend to return with the environment normalising," analysts from ICICI Securities Research noted.
After spending considerable time and energy in remediation efforts in the wake of the US Food and Drug Administration's warning letter on compliance issues, the company's leadership has finally set out to bring the house in order.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances